FibroGen, Inc. (FGEN)
Stock Price:
$40.02 USD
-1.31 (-3.17%)
Updated November 25, 4:00 PM EST - Market closed
Key Info
| Market Cap |
3.64B |
| Revenue (ttm) |
119.30M |
| Net Income (ttm) |
-228.78M |
| Shares Out |
91.01M |
| EPS (ttm) |
-2.57 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 25 |
| Last Price |
$40.02 |
| Previous Close |
$41.33 |
| Change ($) |
-1.31 |
| Change (%) |
-3.17% |
| Day's Open |
41.33 |
| Day's Range |
39.84 - 41.70 |
| Day's Volume |
377,663 |
| 52-Week Range |
22.65 - 51.56 |
More Stats
| Market Cap |
3.64B |
| Enterprise Value |
3.00B |
| Earnings Date (est) |
Mar 3, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
91.01M |
| Float |
83.23M |
| EPS (basic) |
-2.61 |
| EPS (diluted) |
-2.57 |
| FCF / Share |
0.45 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
1.11% |
| Payout Ratio |
n/a |
| Shares Short |
8.06M |
| Short Ratio |
13.37 |
| Short % of Float |
9.68% |
| Beta |
1.70 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
90.07 |
| PS Ratio |
30.53 |
| PB Ratio |
8.16 |
| Revenue |
119.30M |
| Operating Income |
-234.32M |
| Net Income |
-228.78M |
| Free Cash Flow |
40.44M |
| Net Cash |
646.20M |
| Net Cash / Share |
7.10 |
| Gross Margin |
38.70% |
| Operating Margin |
-196.42% |
| Profit Margin |
-191.80% |
| FCF Margin |
33.90% |
| ROA |
-17.17% |
| ROE |
-42.19% |
| ROIC |
-47.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (9)
| Buy |
4 |
| Overweight |
0 |
| Hold |
4 |
| Underweight |
0 |
| Sell |
1 |
Analyst Consensus: Overweight
Price Target
$66.57*
(66.34% upside)
Low
44.0
Current: $40.02
High
92.0
Target: 66.57
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 257 | 213 | 131 | 183 | 181 | 138 | 102 | 65.93 |
| Revenue Growth | 20.48% | 62.57% | -28.49% | 1.31% | 31.41% | 34.68% | 54.96% | - |
| Gross Profit | 255 | 213 | 131 | 183 | 181 | 138 | 102 | 65.93 |
| Operating Income | -89.31 | -86.69 | -117 | -50.04 | -77.63 | -50.10 | -7.95 | -27.22 |
| Net Income | -76.97 | -86.42 | -121 | -58.07 | -85.78 | -59.50 | -14.94 | -32.57 |
| Shares Outstanding | 86.63 | 84.06 | 72.99 | 62.74 | 60.34 | 18.78 | 13.19 | 13.13 |
| Earnings Per Share | -0.89 | -1.03 | -1.66 | -0.93 | -1.42 | -3.17 | -1.13 | -2.48 |
| Operating Cash Flow | -78.71 | -76.14 | -66.51 | 7.11 | -18.57 | 22.41 | 25.92 | -5.61 |
| Capital Expenditures | -5.76 | -7.84 | -8.50 | -1.25 | -1.98 | -8.11 | -6.80 | -0.74 |
| Free Cash Flow | -84.46 | -83.98 | -75.01 | 5.86 | -20.55 | 14.31 | 19.11 | -6.35 |
| Cash & Equivalents | 534 | 621 | 736 | 253 | 181 | 187 | 130 | 47.14 |
| Total Debt | 51.10 | 97.16 | 97.76 | 97.35 | 97.04 | 96.82 | 96.81 | 93.23 |
| Net Cash / Debt | 483 | 524 | 638 | 156 | 84.13 | 90.26 | 33.25 | -46.09 |
| Assets | 857 | 881 | 899 | 470 | 471 | 484 | 297 | 266 |
| Liabilities | 322 | 352 | 351 | 294 | 274 | 243 | 189 | 143 |
| Book Value | 516 | 509 | 528 | 156 | 178 | 221 | -88.71 | -73.95 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
FibroGen, Inc. |
| Country |
United States |
| Employees |
531 |
| CEO |
Enrique A. Conterno |
Stock Information
| Ticker Symbol |
FGEN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: FGEN |
| IPO Date |
November 14, 2014 |
Description
FibroGen, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.